Asthma Control, Quality of Life and Emotional Feelings in a Real Life Setting
Launched by ASTRAZENECA · Dec 22, 2015
Trial Information
Current as of April 30, 2025
Completed
Keywords
ClinConnect Summary
Rationale for this Non-Interventional Study According to the Japanese Asthma Prevention and Management Guideline 2015 (Japan guideline (JGL) 2015), the goal in the management and treatment of asthma is "to be able to lead a life like a healthy individual." In order to achieve this therapeutic goal, the achievement of "well-controlled" state based on the asthma control status is considered to be a clinical goal. However, there are few studies in which the asthma control status is accurately surveyed in a real life setting in adult asthma patients receiving continued treatment from physician ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Provided written consent before starting any procedure specified in the study protocol
- • Aged 20 years or older at the time of providing the consent
- • Receiving treatment for asthma as an outpatient at the time of providing the consent
- • Physician definitive diagnosis of asthma at least 1 year before providing the consent
- • Started to receive treatment with at least 1 of the following asthma drugs at least 1 year before providing the consent
- Exclusion Criteria:
- • Enrolled in this study in the past
- • Assessed by the Investigator to require additional treatment due to worsening of asthma symptoms at the time of providing the consentEnrolled in this study in the past
- • Scheduled to be hospitalized within 2 weeks after providing the consent due to asthma or any other disease
- • Participating in another interventional study such as a clinical study at the time of providing the consent
- • Considered by the Investigator as not appropriate for enrollment in this study due to inability to adhere to the procedures, limitations, and requirements of this study including answering and returning the questionnaires, etc.
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fujisawa, Kanagawa, Japan
Moriguchi, Osaka, Japan
Iwata, Shizuoka, Japan
Sendai, Miyagi, Japan
Fukuoka, , Japan
Kiyose, Tokyo, Japan
Kobe, Hyogo, Japan
Hamamatsu, Shizuoka, Japan
Yokohama, Kanagawa, Japan
Yokohama, Kanagawa, Japan
Shizuoka, , Japan
Fukuoka, , Japan
Okawa, Fukuoka, Japan
Saga, , Japan
Komaki, Aichi, Japan
Toyota, Aichi, Japan
Hachinohe, Aomori, Japan
Chikushino, Fukuoka, Japan
Kurume, Fukuoka, Japan
Kurume, Fukuoka, Japan
Kurume, Fukuoka, Japan
Omuta, Fukuoka, Japan
Omuta, Fukuoka, Japan
Yanagawa, Fukuoka, Japan
Date Gun, Fukushima, Japan
Mizunami, Gifu, Japan
Takasaki, Gunma, Japan
Sapporo, Hokkaido, Japan
Himeji, Hyogo, Japan
Kobe, Hyogo, Japan
Morioka, Iwate, Japan
Sakaide, Kagawa, Japan
Takamatsu, Kagawa, Japan
Takamatsu, Kagawa, Japan
Yokohama, Kanagawa, Japan
Yokohama, Kanagawa, Japan
Fukuoka, Koga, Japan
Tsukubo Gun, Okayama, Japan
Higashi Osaka, Osaka, Japan
Ikeda, Osaka, Japan
Takatsuki, Osaka, Japan
Takatsuki, Osaka, Japan
Cyuo Ku, Tokyo, Japan
Itabashi Ku, Tokyo, Japan
Koganei, Tokyo, Japan
Nakano Ku, Tokyo, Japan
Ota Ku, Tokyo, Japan
Shinjyuku Ku, Tokyo, Japan
Sumida Ku, Tokyo, Japan
Tachikawa, Tokyo, Japan
Fukuoka, , Japan
Fukushima, , Japan
Hiroshima, , Japan
Hiroshima, , Japan
Hiroshima, , Japan
Osaka, , Japan
Saitama, , Japan
Patients applied
Trial Officials
Mitsuru Adachi, MD, PhD, Professor
Principal Investigator
International University of Health and Welfare
Gen Tamura, MD, PhD, President
Principal Investigator
Airway Institute in Sendai Co., Ltd
Masanori Nishikawa, DM, PhD
Principal Investigator
Department of Respiratory Medicine, Fujisawa City Hospital
Soichiro Hozawa, MD
Principal Investigator
Hiroshima Allergy and Respiratory Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials